Radionuclide imaging and treatment of thyroid cancer.
Over the past decades, the diagnostic methods and therapeutic tools for thyroid cancer (TC) have been greatly improved. In addition to the classical method of ingestion of radioactive iodine-131 (I131) and subsequent I123 and I124 positron emission tomography (PET) in therapy and examination, I124 PET-based 3-dimensional imaging, Ga68-labeled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI(3)-octreotide (DOTANOC) PET/computed tomography (CT), Tc99m tetrofosmin, pre-targeted radioimmunotherapy, and peptide receptor radionuclide therapy have all been used clinically. These novel methods are useful in diagnosis and therapy of TC, but also have unavoidable adverse effects. In this review, we will discuss the development of nuclear medicine in TC examination and treatment.
Department of Nuclear Medicine, ShanXi Tumor Hospital, Shan Xi, 030013, China, wangxiujuan_xj@126.com.
Xiu Juan
XJ
Wang
Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shan Xi,030012, China.
XianFeng
X
Li
Yuan
Y
Ren
D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D000072078:Positron Emission Tomography Computed Tomography; D049268:Positron-Emission Tomography; D011877:Radionuclide Imaging / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy*
D007457:Iodine Radioisotopes